In 2020, selumetinib, an MEK inhibitor, was approved in patients with inoperable plexiform neurofibromas affected by neurofibromatosis type 1 (NF1) with hyperactivation of the RAS-MAPK signaling pathway [37]. This evidence concerns the gene NF1 and neurofibromatosis.